As the innovative drug industry chain experiences sustained growth, the Hong Kong market is set to welcome another CDMO player. Zhixiang Biotech (Suzhou) Co., Ltd. has recently submitted its application for a main board listing on the Hong Kong Stock Exchange, with Dongsheng Securities (Hong Kong) acting as the sole sponsor. Since its establishment, the company has completed six rounds of financing, raising a total of approximately 1.231 billion yuan. Its shareholder base includes well-known institutions such as Legend Capital, Gaorong Capital, Qingsong Capital, Boyuan Capital, and Shiyu Capital. Following its Series C+ round in 2024, the company's valuation reached 5.91 billion yuan. As of the latest disclosure, Zhixiang Biotech has an operational capacity of 113,400 liters and a project portfolio of nearly 200 items. The key question for its Hong Kong IPO is whether it can secure genuine market confidence.
Key Factors for Consideration
Public information indicates that Zhixiang Biotech provides one-stop CDMO solutions for biologics development and manufacturing. Its services span the entire lifecycle, including process development, analytical method development and validation, GMP production, quality management, and CMC support. The company has established six proprietary technology platforms covering cell line development, media development, process scale-up, bioconjugation, complex antibody purification, and high-concentration formulation development, forming an integrated technical ecosystem from molecule design to commercial production. Its cell line development platform has supported over 300 molecules with pre-optimization protein expression exceeding 10g/L; the media development platform can increase protein expression by 40%; the process scale-up platform has handled over 150 projects and 500 scale-up batches with a success rate exceeding 98%.
Financial Performance and Debt Position
Fundamentally, the company remains loss-making, and its balance sheet is under significant pressure. From 2023 to 2025, the company generated revenues of approximately 455 million yuan, 433 million yuan, and 484 million yuan respectively, with a year-on-year revenue increase of 11.7% in 2025. However, it recorded net losses of about 168 million yuan, 291 million yuan, and 215 million yuan for the same periods, accumulating a total loss of 674 million yuan over three years. As of the end of 2025, total assets stood at 3.002 billion yuan against total liabilities of 3.771 billion yuan, resulting in a debt-to-asset ratio of 125.61%. Net debt expanded from 267 million yuan in 2023 to 769 million yuan in 2025, while net current liabilities increased from 1.217 billion yuan to 1.242 billion yuan. Within the liability structure, bank borrowings and interest-bearing debt grew from 1.12 billion yuan at the end of 2023 to 1.657 billion yuan by the end of 2025, accounting for 44% of total liabilities.
Root Cause of Losses and Expansion Strategy
The primary reasons for the sustained losses and high debt levels stem from substantial prior investments in capacity construction. The company has established three major production parks in Suzhou, Changshu, and Xiangcheng, covering approximately 121,300 square meters of GMP facilities with a total operational capacity of 113,400 liters. Notably, the Changshu facility alone has an installed capacity of 85,300 liters, making it the largest single-site capacity among domestic CDMOs. According to its prospectus, the company's current capacity utilization is at a relatively high industry level, with four production lines reaching utilization rates of 94.2%, 75.8%, 76.2%, and 91.8% in 2025. The company estimates that its existing capacity will approach saturation by the fourth quarter of 2028. Consequently, it plans to use IPO proceeds to further expand bulk drug substance capacity, establish a dedicated ADC drug production system, and enhance intelligent R&D infrastructure to diversify its service offerings and capture future incremental orders.
Challenges of Further Expansion
However, given that the initial capacity build-out has already strained profitability and finances, a new round of expansion implies further capital expenditure, increased depreciation and amortization pressures, and a heavier debt burden. This could potentially exacerbate the company's imbalance between profits and losses.
Industry Landscape and Competitive Dynamics
The rapid development of the innovative drug industry has generated massive outsourcing demand for CDMOs. The commercialization of novel drugs requires significant capital for capacity build-out, environmental assessments, GMP certification, production line maintenance, and specialized talent recruitment, leading many biotech startups to outsource commercialization and production to CDMO firms. Since 2025, with the gradual improvement in the global biopharma financing environment, the CDMO sector has been experiencing a recovery. Data shows the global biologics CDMO market size expanded from $18 billion in 2020 to $31.8 billion in 2025, representing a CAGR of 12.1%, and is projected to reach $63.5 billion by 2030 and $105.8 billion by 2035. The growth in the Chinese market is even more pronounced, jumping from 9.1 billion yuan to 32.5 billion yuan over the same period, a CAGR of 28.9%, with forecasts of 88 billion yuan by 2030 and potentially exceeding 216.4 billion yuan by 2035.
Market Concentration and Project Mix
Despite the industry's expansion, China's biologics CDMO sector exhibits a clear concentration at the top. Based on 2025 revenue, the top two players focused on antibody drugs collectively hold a 67.3% market share. Zhixiang Biotech, ranked third, holds only a 1.5% share. Overcoming the first-mover advantages, economies of scale, and customer loyalty established by the leading firms presents a significant challenge for mid-tier companies. Furthermore, Zhixiang Biotech's current project portfolio is predominantly early-stage. Such projects typically involve smaller order sizes and lower pricing, and the revenue generated may struggle to cover the high fixed operating costs. As disclosed in the prospectus, of the 197 projects in hand as of the end of 2025, pre-IND (87) and Phase I/II (84) projects together accounted for 86.8%. Only 24 projects were in late-stage development (Phase III and BLA), with merely 2 having reached commercialization.
R&D Investment and Industry Evolution
Additionally, the year-on-year decline in R&D investment might cause Zhixiang Biotech to fall behind in the industry's shift towards higher-value services. From 2023 to 2025, the company's R&D expenses were 57.859 million yuan, 37.102 million yuan, and 45.915 million yuan, representing 12.7%, 8.6%, and 9.5% of annual revenue, respectively. The overall CDMO industry trend shows a shift. Previously, the domestic CDMO industry was primarily focused on chemical APIs and small molecule drug manufacturing, with relatively low barriers to entry. With global biopharmaceutical technological advancements, the industry focus is gradually shifting to cutting-edge areas like peptides, oligonucleotides, and cell and gene therapies (CGT). In line with this trend, industry leaders are making significant investments to strategically position themselves in these high-value emerging fields.
Outlook and Investment Considerations
In this industry reshuffle driven by technological upgrades, the trend of resources and orders concentrating towards the top players is likely to intensify, posing greater operational pressure for mid-sized and smaller CDMOs like Zhixiang Biotech. Objectively, while the company is currently loss-making and under financial strain, the backdrop of industry expansion, coupled with its existing 113,400-liter capacity and nearly 200 projects, provides considerable potential for future performance growth. With over 80% of its current projects in preclinical and early stages, the future value realization hinges on the progression of client pipelines towards later stages and eventual commercialization. If the company successfully lists in Hong Kong, subsequent focus should be on the clinical advancement pace of its existing project portfolio and the efficiency of their commercialization conversion.